PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

A case report of apatinib in treating osteosarcoma with pulmonary metastases.

Abstract Osteosarcoma is the most common malignant bone tumor in children and adolescents. Pulmonary metastases lead to a significantly increased risk of death. Apatinib, a new potent oral small-molecule tyrosine kinase inhibitor targeting the intracellular domain of vascular endothelial growth factor receptor 2 (VEGFR-2), shows survival benefits in treating advanced or metastatic gastric adenocarcinoma, non-squamous non-small cell lung cancer and metastatic breast cancer. However, its efficacy in metastatic osteosarcoma has not been reported yet.
PMID
Related Publications

Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.

Significant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib: A case report.

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.

The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 28403086
OWN - NLM
STAT- MEDLINE
DA  - 20170413
DCOM- 20170428
LR  - 20170430
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 15
DP  - 2017 Apr
TI  - A case report of apatinib in treating osteosarcoma with pulmonary metastases.
PG  - e6578
LID - 10.1097/MD.0000000000006578 [doi]
AB  - RATIONALE: Osteosarcoma is the most common malignant bone tumor in children and
      adolescents. Pulmonary metastases lead to a significantly increased risk of
      death. Apatinib, a new potent oral small-molecule tyrosine kinase inhibitor
      targeting the intracellular domain of vascular endothelial growth factor receptor
      2 (VEGFR-2), shows survival benefits in treating advanced or metastatic gastric
      adenocarcinoma, non-squamous non-small cell lung cancer and metastatic breast
      cancer. However, its efficacy in metastatic osteosarcoma has not been reported
      yet. PATIENT CONCERNS: Herein, we presented a 50-year-old man patient who visited
      hospital due to local bone pain in the left leg. DIAGNOSES: He was initially
      diagnosed with osteoblastic osteosarcoma. INTERVENTIONS: The patient suffered
      repeated resection surgeries but developed multiple lung metastases. Positive
      staining for CD31, CD34, and VEGFR-2 were detected in the tumor section. As he
      refused to receive chemotherapy due to concerns regarding the chemotherapy
      toxicities and sorafenib due to high cost, apatinib was given at a dose of 500 mg
      daily. OUTCOMES: Eleven months following apatinib administration, the patient
      achieved a partial response according to the RECIST 1.1 standard. No severe
      toxicity or drug-related side effect was observed during the treatment. LESSONS: 
      Therefore, apatinib could be a new option for the treatment of metastatic
      osteosarcoma. Clinical trials are required to further confirm the efficacy and
      safety of apatinib in treating pulmonary metastases from osteosarcoma.
FAU - Zhou, Yong
AU  - Zhou Y
AD  - aDepartment of Orthopedics bPrecision Medicine Center, West China Hospital,
      Sichuan University, Chengdu, Sichuan, China.
FAU - Zhang, Wengeng
AU  - Zhang W
FAU - Tang, Fan
AU  - Tang F
FAU - Luo, Yi
AU  - Luo Y
FAU - Min, Li
AU  - Min L
FAU - Zhang, Wenli
AU  - Zhang W
FAU - Shi, Rui
AU  - Shi R
FAU - Duan, Hong
AU  - Duan H
FAU - Tu, Chongqi
AU  - Tu C
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Pyridines)
RN  - TK02X14ASJ (apatinib)
SB  - AIM
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Femoral Neoplasms/*drug therapy/pathology
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/secondary
MH  - Male
MH  - Middle Aged
MH  - Osteosarcoma/*drug therapy/secondary
MH  - Pyridines/*therapeutic use
MH  - Treatment Outcome
PMC - PMC5403083
EDAT- 2017/04/14 06:00
MHDA- 2017/04/30 06:00
CRDT- 2017/04/14 06:00
AID - 10.1097/MD.0000000000006578 [doi]
AID - 00005792-201704140-00019 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Apr;96(15):e6578. doi: 10.1097/MD.0000000000006578.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>